HRTX

Heron is a real commercial business, not a pre-revenue story: FY2025 net product sales reached $155M (+7.4%) at a 73.3% gross margin, and the operating loss was nearly eliminated — falling 78% to just -$2.54M (-1.6% of sales) from -$11.5M a year earlier. The MD&A shows the engine of that improvement is a 65.1% surge in Acute Care (ZYNRELEF, APONVIE) plus a 25.5% cut in R&D, which offset a 7.8% decline in the Oncology franchise (CINVANTI/SUSTOL) that still makes up the majority of sales ($105M of $155M). At a 0.5x P/S and an $82M market cap, the operating-leverage story is priced for failure, which is the core of the bull case.

But the quality of the balance sheet and cash flows is poor enough to keep this off the buy list. Net loss actually widened to -$20.2M (from -$13.6M) because operating progress was swamped by an $11.3M loss on debt extinguishment and $3.6M more interest expense — a reminder that the capital structure, not the product P&L, drives the bottom line. Liabilities-to-equity sits at 16.85x against just $14.3M of stockholders' equity, and the accumulated deficit is -$1.94B. Operating cash flow was -$27.6M, worse than the prior year, against the $46.6M of cash and short-term investments management cites — roughly 1.5 years of runway and exactly the 'at least one year' wording that signals a financing need ahead. Shares already grew 23.8% in a year, so dilution is the most likely path to fund the gap, directly diluting any per-share upside.